Literature DB >> 12032195

Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality.

Andrea Gerdemann1, Zoltan Wagner, Andreas Solf, Udo Bahner, August Heidland, Jörg Vienken, Reinhard Schinzel.   

Abstract

BACKGROUND: Advanced glycation end products (AGEs) accumulate in patients with end-stage renal disease (ESRD). The aim of this study was to investigate the potential influence of different modalities of renal replacement therapies on plasma AGE levels.
METHODS: The removal of AGEs by high-flux haemodialysis (HD) using standard and ultrapure dialysis fluid (SDF and UDF), by haemodiafiltration (HDF) and by haemofiltration (HF) was studied by fluorescence spectroscopy and by a carboxymethyllysine (CML)-specific ELISA. In addition, molecular weight distribution of fluorescent AGE products in serum of several patients was analysed by gel filtration.
RESULTS: The highest AGE-typical fluorescence was found in the serum of patients on HD using SDF (114,667+/-18,967 arbitrary units (AU)), followed by patients on HDF (86,912+/-24,411 AU, P<0.005), by patients on HD using UDF (74,953+/-21,152 AU, P<0.0001) and by patients on HF (74 039+/-17 027 AU, P<0.0001). Similar results were found for serum CML levels with the highest values in HD patients on SDF (1609+/-504 ng/ml), followed by patients on HF (1354+/-614 ng/ml, P<0.001), then by HD patients on UDF (1310+/-403 ng/ml, P<0.001) and by patients on HDF (1132+/-338 ng/ml, P<0.001). The removal rate of AGEs, as evaluated by the determination of the pre-/post-dialysis AGE differences, was comparable across all groups.
CONCLUSION: These findings suggest that factors other than removal are responsible for the lower pre-dialysis AGE levels found in patients on convective dialysis as well as on HD with UDF. A role of water quality is assumed. This is corroborated by the finding that the high molecular weight AGE-fraction is preferentially lowered in comparison with patients on HD with SDF, as analysed by gel filtration chromatography. These findings could be best explained by a less severe oxidative stress (i.e. resulting in decreased AGE generation) with HF and HDF, as well as with ultrapure HD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032195     DOI: 10.1093/ndt/17.6.1045

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients.

Authors:  Ryuichi Furuya; Hiromichi Kumagai; Toshio Miyata; Hirotaka Fukasawa; Shinsuke Isobe; Naoko Kinoshita; Akira Hishida
Journal:  Clin Exp Nephrol       Date:  2011-12-09       Impact factor: 2.801

2.  Cardiorenal syndrome type 4: a review.

Authors:  Anna Clementi; Grazia Maria Virzì; Ching Yan Goh; Dinna N Cruz; Antonio Granata; Girogio Vescovo; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2013-04       Impact factor: 2.041

3.  Prognostic potential and tumor growth-inhibiting effect of plasma advanced glycation end products in non-small cell lung carcinoma.

Authors:  Babett Bartling; Hans-Stefan Hofmann; Antonia Sohst; Yvonne Hatzky; Veronika Somoza; Rolf-Edgar Silber; Andreas Simm
Journal:  Mol Med       Date:  2011-05-24       Impact factor: 6.354

Review 4.  Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.

Authors:  Sandeep K Mallipattu; John C He; Jaime Uribarri
Journal:  Semin Dial       Date:  2012-04-30       Impact factor: 3.455

5.  Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation.

Authors:  A Heidland; K Sebeková; A Frangiosa; L S De Santo; M Cirillo; F Rossi; M Cotrufo; A Perna; A Klassen; R Schinzel; N G De Santo
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

6.  Effectiveness of arginase inhibitors against experimentally induced stroke.

Authors:  Waleed Barakat; Ahmad Fahmy; Mohamed Askar; Sherif El-Kannishy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-29       Impact factor: 3.000

7.  Unchanged serum levels of advanced glycation endproducts in patients with liver disease.

Authors:  Moritz Butscheid; Christian Schäfer; Stefanie Brenner; Dominik Alscher; Thomas Mürdter; Toshimitsu Niwa; Matthias Frischmann; Monika Pischetsrieder; Ulrich Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-15       Impact factor: 3.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.